Lawsuit investigation launched over ADMA Biologics' alleged misleading revenue claims causing stock drop

The Rosen Law Firm is investigating a potential class action lawsuit against ADMA Biologics after allegations surfaced that the company engaged in channel stuffing to inflate revenue. This claim was highlighted in a report by short seller Culper Research, which caused ADMA's stock to drop 16.6% on March 24, 2026. Investors who suffered losses may be eligible for compensation through the lawsuit. The Rosen Law Firm is encouraging affected shareholders to join the class action to seek recovery of their losses.